Australia markets close in 55 minutes

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.6700+0.0400 (+2.45%)
At close: 04:00PM EDT
1.7300 +0.06 (+3.59%)
After hours: 07:30PM EDT

Soleno Therapeutics, Inc.

203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
650 213 8444

Full-time employees20

Key executives

NameTitlePayExercisedYear born
Dr. Anish Bhatnagar M.D.Pres, CEO, COO & Director618.7kN/A1970
Mr. James H. MacKanessChief Financial Officer392kN/A1964
Ms. Kristen Yen M.S.VP of Clinical Operations317.19kN/A1969
Ms. Patricia C. HiranoVP of Regulatory Affairs343.35kN/A1966
Mr. Anthony WondkaSr. VP & GMN/AN/A1962
Dr. Neil M. Cowen M.B.A., Ph.D., MBASr. VP of Drug Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Corporate governance

Soleno Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.